The 501Y.V2 SARS-CoV-2 variant identified in South Africa has researchers worried it could bypass protection from prior infection or vaccination,
Doctors say they help. So why are COVID-19 treatments—including monoclonal antibodies, antivirals, and corticosteroids—going unused?
The long weekend was a busy one for vaccine news—here’s the latest:
A Chinese-made coronavirus vaccine has an efficacy rate just over 50%—far lower than the 78% anticipated, according to a Brazilian clinical trial conducted by São Paulo’s Butantan Institute.
The issue is far from settled among economists and politicians, as NPR repor
Amid supply shortages and persistent vaccine nationalism, it could be years before COVID-19 vaccines reach billions of people in low- and middle-income countries, the
A double-blind trial of 160 patients in Argentina offered promising results for convalescent plasma as a COVID-19 treatment,
As the UK deployed its first COVID-19 vaccines yesterday, the University of Oxford and AstraZeneca revealed that their vaccine had 70% efficacy—on average—against symptomatic illness and could substantially reduce hospitalizations,
The UK vaulted over the US today in the race to immunize citizens against COVID-19 after it became the first Western country to approve the Pfizer/BioNTech vaccine under emergency authorization.
The AstraZeneca/Oxford University COVID-19 vaccine has up to 90% efficacy against SARS-CoV-2—and would be easier to distribute than other promising candidates, according to interim results from a Phase 3 vaccine trial.